XBiotech Valuation
| XBIT Stock | USD 3.02 0.04 1.31% |
At this time, the entity appears to be undervalued. XBiotech maintains a prevalent Real Value of $6.73 per share. The last-minute price of the entity is $3.02. Our model calculates the value of XBiotech from examining the entity fundamentals such as Current Valuation of (81.06 M), shares owned by insiders of 35.16 %, and Return On Asset of -0.12 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting XBiotech's valuation include:
Price Book 0.4792 | Enterprise Value | Enterprise Value Ebitda (1.60) | Price Sales 12.2321 | Enterprise Value Revenue 24.051 |
Undervalued
Today
Please note that XBiotech's price fluctuation is moderately volatile at this time. Calculation of the real value of XBiotech is based on 3 months time horizon. Increasing XBiotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
XBiotech's intrinsic value may or may not be the same as its current market price of 3.02, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.02 | Real 6.73 | Target 18.0 | Hype 2.9 | Naive 2.97 |
The intrinsic value of XBiotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence XBiotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of XBiotech helps investors to forecast how XBiotech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XBiotech more accurately as focusing exclusively on XBiotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use XBiotech's intrinsic value based on its ongoing forecasts of XBiotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against XBiotech's closest peers.
XBiotech Cash |
|
XBiotech Valuation Trend
XBiotech's real value is important for investors to make better decisions and a more accurate overall view of XBiotech's financial worth over time. Using both XBiotech's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
XBiotech Total Value Analysis
XBiotech is at this time forecasted to have valuation of (81.06 M) with market capitalization of 92.06 M, debt of 7.77 M, and cash on hands of 225.79 M. The negative valuation of XBiotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the XBiotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(81.06 M) | 92.06 M | 7.77 M | 225.79 M |
XBiotech Investor Information
About 35.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.48. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XBiotech recorded a loss per share of 1.08. The entity last dividend was issued on the 15th of July 2021. XBiotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.XBiotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. XBiotech has an asset utilization ratio of 0.13 percent. This implies that the Company is making $0.001324 for each dollar of assets. An increasing asset utilization means that XBiotech is more efficient with each dollar of assets it utilizes for everyday operations.XBiotech Ownership Allocation
XBiotech retains a total of 30.48 Million outstanding shares. XBiotech owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.XBiotech Profitability Analysis
The company reported the previous year's revenue of 300 K. Net Loss for the year was (24.56 M) with profit before overhead, payroll, taxes, and interest of 3.36 M.About XBiotech Valuation
The stock valuation mechanism determines XBiotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of XBiotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of XBiotech. We calculate exposure to XBiotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XBiotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2 M | -1.9 M | |
| Pretax Profit Margin | (9.63) | (9.15) | |
| Operating Profit Margin | (9.89) | (9.40) | |
| Net Loss | (9.44) | (8.96) | |
| Gross Profit Margin | 0.75 | 0.46 |
XBiotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as XBiotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.4 M |
XBiotech Current Valuation Indicators
XBiotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final XBiotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as XBiotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use XBiotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes XBiotech's worth.Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.